OLEMA PHARMACEUTICALS INC (OLMA)
Health Care · Clinical-stage oncology / breast cancer therapeutics · NASDAQ
Olema Pharmaceuticals is developing next-generation targeted therapies, including a dual-action CERAN/SERD, to transform the treatment of endocrine-driven breast cancers.
What OLEMA PHARMACEUTICALS INC does
Olema is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing next-generation targeted therapies for breast cancer and beyond. The company's lead candidate, palazestrant, is a small-molecule oral drug with dual activity as a complete estrogen receptor (ER) antagonist and selective ER degrader currently in late-stage clinical trials for ER+/HER2− metastatic breast cancer both as monotherapy and in combination with targeted agents. Olema is also developing OP-3136, a KAT6 inhibitor, and leverages its expertise in endocrine-driven cancers and mechanisms of acquired resistance.
Themes: Breast cancer / ER+ metastatic breast cancer, Estrogen receptor antagonists / endocrine therapy, Targeted oncology, Nuclear receptor modulation, Acquired resistance mechanisms, Epigenetic modulation / KAT6 inhibition
Fundamentals
- Price$10.69 as of 2026-08-21 close
- Market cap$935M as of 2026-08-21
- 1-year return+93.0% 2025-08-21 close $5.54 → 2026-08-21 close $10.69
- P/En/a earnings data not available
- ROE-46.0% as of 2026-08-24
- Debt / equity0.01 as of 2026-08-24
- Beta1.97 as of 2026-08-24
- Last reported earnings2026-08-10 SEC EDGAR Form 8-K (Item 2.02)
How OLMA compares in its sector
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How OLEMA PHARMACEUTICALS INC looks technically
OLEMA PHARMACEUTICALS INC (OLMA) is trading 39.0% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 67 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 43, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 9 trading days ago (its momentum flipped negative). It made a new 20-day low about 9 trading days ago. It is 70.5% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 39.0% below its 200-day average, the long-term trend line — a long-term downtrend | -39.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $11.28 | $11.28 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $17.53 | $17.53 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 10.71. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible downward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 67 trading days ago — a "death cross", a bearish long-term signal | 67 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with sellers in control | 26.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 43, neither overbought (above 70) nor oversold (below 30) | 43.2 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($9.70 to $12.21) — its "stochastic" reading is 39 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 39.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 9 trading days ago (its momentum flipped negative) | 9 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $36.26 | $36.26 |
|---|---|---|
| From the 52-week high | it is 70.5% below its 52-week high (its highest price of the past year) | -70.5% |
| Above the 52-week low | it is 107.6% above its 52-week low (its lowest price of the past year) | +107.6% |
| Below the 52-week high | it is 70.5% below its highest point of the past year | 70.5% |
| Since a 20-day breakout | it made a new 20-day low about 9 trading days ago | 9 sessions |
| Since a 55-day breakout | it made a new 55-day low about 47 trading days ago | 47 sessions |
| All-time high | its highest closing price on record is $54.34 (set on 2021-02-22) | $54.34 |
| Given back of the 52-week move | over the past year its closes ranged ($5.26 to $35.83), and it has given back almost all of its rise from last year’s low — 82% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $15.96 to $16.94. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 82.2% |
| From the all-time high | it is 80.3% below its all-time high | -80.3% |
| Nearest price level | it is trading 2.3% below a resistance level at $10.94 — a price it turned at three times since 2024-09-04, most recently on 2024-12-06. Since 2024-08-21 it has 6 such levels below the current price and 6 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +2.3% |
| All-time low | its lowest closing price on record is $2.00 (set on 2022-05-09) | $2.00 |
| Above the all-time low | it is 434.5% above its all-time low | +434.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 71% of it) | 29th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.6554 between its high and its low — about 6.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.6554 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $10.13 and $12.35 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $10.13 – $11.24 – $12.35 |
| Typical daily range (% of price) | its price moves about 6.1% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.1% |
| Stretch from the 200-day average | it is trading 10.4 daily ranges below its 200-day average price (39.0% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 10.4 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.74× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 2.2% since the prior reading | -2.2% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 9 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 9 sessions ago |
|---|---|---|
| Since a bullish engulfing | 6 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 6 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|---|---|
| Open gap | it gapped 8.0% below the previous close 8 sessions ago and has not traded back through the level it left behind at 11.94 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -8.0% |
| Gap filled | a 2.4% gap up opened on 2026-08-19 has been "filled" today — price traded back through the level the gap left behind, and it took 2 sessions to close | today |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -5.48% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 10.1 percentage points (the stock lost 7.8% while the market gained 2.3%) | -10.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 27.1 percentage points (the stock lost 24.0% while the market gained 3.1%) | -27.1% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 66.7 percentage points (the stock lost 55.6% while the market gained 11.1%) | -66.7% |
| vs market, 12 months | over the past 12 months this stock beat the market by 72.5 percentage points (the stock gained 93.0% while the market gained 20.5%) | +72.5% |
Signal agreement
2
| Bullish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bullish state — these describe past price behaviour, not a forecast | 0 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: a strong downtrend, with sellers in control, a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 7.3% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 7.6% of the share price. | -7.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 34% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $16.23 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | -34.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% below the average price paid since it last reported on 2026-08-10 (its 10-Q), so the typical buyer over that stretch is under water. That average is $10.77 — a volume-weighted average of daily closes over 10 sessions, not a true tick-by-tick VWAP. | -0.7% |
Price levels it has turned at before
OLMA last closed at $10.69 on 2026-08-21. Since 2024-08-21 it has turned at 6 prices below its last close and 6 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $10.94 | Resistance | 2.3% above the last close | turned there three times · 2024-09-04 to 2024-12-06 |
| $12.58 | Resistance | 17.7% above the last close | turned there twice · 2026-05-19 to 2026-07-27 |
| $13.00 | Resistance | 21.6% above the last close | turned there four times · 2024-10-23 to 2026-07-07 |
| $6.68 | Support | 37.5% below the last close | turned there twice · 2025-02-05 to 2025-10-20 |
| $5.61 | Support | 47.5% below the last close | turned there three times · 2024-12-19 to 2025-08-05 |
| $4.77 | Support | 55.4% below the last close | turned there three times · 2025-02-13 to 2025-06-26 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $10.71.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $10.37 and $10.71 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close below $9.70.
This reading has stood for 1 trading day, since 2026-08-21.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Analyst price target recently CUT · lagging the market · Most volatile (6%+ typical daily range) · Stretched far below its 200-day average (6+ daily ranges) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.33 mean, 1=Strong Buy…5=Strong Sell) — 10 analysts
- Mean price target$39.30 range $20.00 – $59.00; median $40.00
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for OLMA
- Consensus EPS estimate-$0.5638 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical trial failure: OPERA-01 and OPERA-02 Phase 3 trials may not meet efficacy or safety endpoints, delaying or preventing FDA approval and commercial launch of palazestrant in 2027–2029.","Regulatory and development timelines: Achievement of FDA approval and commercialization depends on successful NDA submission and regulatory review; delays or unfavorable decisions could significantly impact the company's path to profitability.","Competition from established therapies: The company faces competition from major pharmaceutical firms already offering CDK4/6 inhibitors and other ER+/HER2− breast cancer treatments, which may limit market penetration and pricing power for palazestrant."]
What changed in the latest 10-Q
AI-assisted comparison of OLMA's 10-Q filed 2026-05-12 against the prior one filed 2025-11-10.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to audited financial statements for fiscal year ended December 31, 2025, filed March 16, 2026 (newer filing)
- Statement that palazestrant is 'currently being investigated' with specific patient populations and disease indications (newer filing)
- Reference to presentation at AACR Annual Meeting in April 2026 showing OP-3136 in combination with palazestrant with synergistic anti-tumor activity (newer filing)
- Statement expecting to present initial clinical results from OP-3136 Phase 1 study at 2026 ASCO Annual Meeting in May (newer filing)
- Mention of Novartis agreement announced in December 2024 and OPERA-02 initiated in 2025 with ribociclib supply details (newer filing)
- Removed:
- Aspiration statement 'We aspire to transform the treatment paradigm for metastatic breast cancer (MBC)' (older filing)
- Reference to product candidate 'OP-1250' designation for palazestrant (older filing)
- Reference to 'non-clinical models' (older filing used this terminology)
- Details about OPERA-01 Part 2 dose selection of 90mg once-daily (older filing)
- Clinical trial collaboration and supply agreement with Pfizer Inc. for atirmociclib evaluation (older filing)
- Plan to initiate Pfizer Phase 1b/2 study in fourth quarter of 2025 (older filing)
- San Antonio Breast Cancer Symposium (SABCS) December 2024 presentation details (older filing)
- TD Cowen 45th Annual Health Care Conference March 2025 disclosure with specific mPFS data as of February 18, 2025 (older filing)
- Detailed mPFS results from October 2025 ESMO presentation with specific cohort breakdowns (older filing)
- Statement that Novartis agreement was 'entered into in November 2024' (older filing)
- Reworded:
- Changed 'non-clinical models' to 'pre-clinical models' for palazestrant description (newer filing)
- Changed reference from 'OPERA-01 is ongoing' with dose selection details to 'In November 2023, we initiated OPERA-01' with timing expectations (newer filing)
- Changed phrasing of anticipated FDA approval from 'anticipate U.S. Food and Drug Administration (FDA) approval and commercial launch' to 'anticipate potential U.S. Food and Drug Administration (FDA) approval and commercial launch' (newer filing added 'potential')
- Changed 'In combination, we are investigating' to 'In addition, we are investigating' regarding combination studies (newer filing)
- Rephrased CDK4 inhibitor reference from 'Pfizer's investigative selective CDK4 inhibitor' to simply mentioning 'a CDK4 inhibitor (atirmociclib)' (newer filing, removed Pfizer partnership language)
- Changed ESMO reference timing from presentation details to summary statement about October 2025 presentation (newer filing condensed the disclosure)
- Changed 'entered into in November 2024' to 'announced in December 2024' for Novartis agreement date (newer filing)
- Notes:
- The newer filing appears to be a 10-Q for Q1 2026 (ended March 31, 2026) while older filing is a 10-Q for Q3 2025 (ended September 30, 2025), making some timeline updates expected
- Text appears truncated in both filings at the end of the Management's Discussion section, potentially limiting completeness of comparison
Risk Factors
- Added:
- Added reference to 'NDA' spelled out as 'New Drug Application (NDA)' in older version, simplified to just 'NDA' in newer version (2026-05-12)
- Added phrase 'and prospects' after 'results of operations' in multiple risk factor bullet points (2026-05-12)
- Added 'and prospects' to macroeconomic conditions risk factor (2026-05-12)
- Added specification that IT systems belong to 'our' company in the cybersecurity risk factor (2026-05-12)
- Removed:
- Removed '(OP-1250)' identifier after 'palazestrant' in the detailed risk factor description (2026-05-12)
- Removed 'and clinical trials' after 'conducting non-clinical studies' in the product development history (2026-05-12)
- Removed 'if approved' context from commercialization expenses language at end of capital requirements section (2026-05-12)
- Reworded:
- Changed 'and, as a result,' to 'and, as a result,' punctuation formatting in regulatory approvals risk (2026-05-12)
- Changed 'would be if' to 'could be if' in predicting future success language (2026-05-12)
- Changed 'if approved' to 'if, approved' formatting in going concern transition language (2026-05-12)
- Changed 'and supporting commercial operations, if approved' to 'and supporting commercial operations,' removing the conditional 'if approved' (2026-05-12)
- Changed 'OP-3136 or other product candidates' to 'OP-3136, or any future product candidates we may develop' in commercialization expenses context (2026-05-12)
- Reordered risk factor bullet regarding IT systems from 'or those third parties' to 'our data or those of the third parties' (2026-05-12)
- Changed 'or product candidates we may develop in the future' to 'or any future product candidates we may develop' in competition risk (2026-05-12)
- Notes:
- Both texts appear truncated at the end of the capital requirements section; full comparison of subsequent text not possible
- Page numbers differ between filings (44-45 in newer vs. 42-43 in older), suggesting document restructuring
- Some changes appear to be minor formatting/punctuation standardizations rather than substantive content modifications
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 2 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 2 sells ($291163) — 1 selling insider
- Last 180 days0 buys · 2 sells ($291163) — 1 selling insider
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-24. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about OLMA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding OLMA as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 21,083,143
- Reported value $314,349,660
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 1 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
OLMA had 15,963,215 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
OLMA had 18.2% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 18.21 days to cover at the same settlement.
- Reported short interest (shares) 15,963,215
- Short interest (% of shares outstanding) 18.2%
- Prior settlement (shares) 15,101,848
- Reported change 5.7%
- Days to cover (reported) 18.21
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Menarini Group (Elacestrant)
- Roche (Genentech)
- Pfizer (PFE)
- Novartis (NVS)
- Eli Lilly (LLY)
- AstraZeneca (AZN)
- Arcus Biosciences (RCUS)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare OLMA vs…
Frequently asked questions
What does OLEMA PHARMACEUTICALS INC (OLMA) do?
Olema is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing next-generation targeted therapies for breast cancer and beyond. The company's lead candidate, palazestrant, is a small-molecule oral drug with dual activity as a complete estrogen receptor (ER) antagonist and selective ER degrader currently in late-stage clinical trials for ER+/HER2− metastatic breast cancer both as monotherapy and in combination with targeted agents.
What sector is OLEMA PHARMACEUTICALS INC (OLMA) in?
OLEMA PHARMACEUTICALS INC (OLMA) is classified in the Health Care sector. Its industry is Clinical-stage oncology / breast cancer therapeutics. It trades on NASDAQ.
Who are OLEMA PHARMACEUTICALS INC's (OLMA) competitors?
Notable peers of OLEMA PHARMACEUTICALS INC (OLMA) include Menarini Group (Elacestrant), Roche (Genentech), Pfizer, Novartis and Eli Lilly. This peer set is informational only — not financial advice.
Is OLEMA PHARMACEUTICALS INC (OLMA) overbought or oversold right now?
OLEMA PHARMACEUTICALS INC (OLMA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 43, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on OLMA come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.